Inhaling cannabis is associated with the remission of refractory idiopathic angioedema, according to a clinical report published in the journal Case Reports in Immunology. Angioedema is a condition characterized by rapid swelling under the skin in regions around the face and throat, which may result in airway obstruction or suffocation.
Investigators from the Soroka University Medical Center in Israel reported on the progress of a 27-year-old male patient with life-threatening, recurrent angioedema of unknown origin. Doctors placed the patient on a regiment of 20 grams of inhaled cannabis monthly after he failed to respond favorably to prescribed steroids and antihistamines.
Authors reported: “The use of inhaled cannabis resulted in a complete response, and he has been free of symptoms for 2 years. An attempt to withhold the inhaled cannabis led to a recurrent attack within a week, and resuming cannabis maintained the remission, suggesting a cause and effect relationship.”
They concluded: “This is the first report in which a cannabis product for the treatment of refractory idiopathic angioedema was associated with an excellent clinical response. … More research into the exact mechanism of action of cannabis products in cases of idiopathic angioedema and on the modulation of the immune response in general is indicated.”
The Israeli government has authorized the limited production and distribution of marijuana as a medical treatment since 2011, and preparations of the plant are expected to be available in pharmacies imminently.
Full text of the report, “Life threatening idiopathic recurrent angioedema responding to cannabis,” appears online here.
UPDATE: Join the NORML Nation HERE!
One of the most valuable resources that NORML possesses is our members. They are our lifeblood and the driving force behind the multitude of statewide and local reform efforts taking place around the country. That’s why NORML is pushing to build our ranks in advance of the 2016 election by launching the weeklong NORML Nation Membership Drive. As many of you know, presidential elections tend to attract a larger pool of younger and more politically progressive voters. We hope to tap into this expected voting block to achieve unprecedented successes in 2016.
2016 will be a watershed year for ending marijuana prohibition at the local, state and federal level. NORML and NORML chapters are engaging in multistate strategy to assist with marijuana-related ballot initiatives and legislative reform efforts, and we and the NORML PAC are pushing for federal reform by lobbying members of Congress in support of The CARERS Act, The Marijuana Businesses Access to Banking Act, and The Regulate Marijuana Like Alcohol Act, as well as additional budgetary amendments and regulatory reforms.
Funds that we raise through this membership drive will help us cover costs related to our ongoing lobbying efforts and expand our network of NORML Chapters. Also, a portion of the proceeds will be used to establish our Chapter Grant program which will dedicated to directly supporting NORML-led local reform efforts.
If you’re already NORML Chapter Leader or Member, you can earn money for your local NORML Chapter through the NORML Nation Chapter Contest! The top three chapters with the most referrals to the NORML Nation will earn $1,000, $500, and $250! I’ll be sending around an email to Chapter Leaders with more information about the NORML Nation Chapter Contest.
Thank you in advance for helping us make this a successful membership drive. You can help us reach our goal by encouraging others to become members of NORML and to donate to our work. You can also join the NORML Nation Membership Drive Facebook event, and invite your friends!
Democrat Gov. Jerry Brown signed legislation today, Assembly Bill 258, to allow medical marijuana patients to receive organ transplants.
Hospitals in California and elsewhere have denied patients from receiving organ transplants solely based on their status as medicinal marijuana consumers. Assembly Bill 258 reads, “A hospital, physician and surgeon, procurement organization, or other person shall not determine the ultimate recipient of an anatomical gift based solely upon a potential recipient’s status as a qualified patient, as defined in Section 711362.7, or based solely upon a positive test for the use of medical marijuana by a potential recipient who is a qualified patient.”
Passage of AB 258 ends these discriminatory practices in California.
The new law takes effect on January 1, 2016.
According to a study published in the American Journal of Transplantation, marijuana use by patients undergoing transplants does not adversely impact survival rates.
While the US government effectively bans scientific research regarding cannabis and any potential therapeutic uses, you can help University of Texas at Dallas associate professor of Criminology Dr. Robert Morris, II conduct another in a series of cannabis policy research-related questions.
This time around Dr. Morris and his colleagues are asking the sensible question public policy question: ‘Does Medical Cannabis Legalization Impact Police Officer Safety?’
NORML’s curious, aren’t you too?
Let’s help fund the research via crowdsourcing and find out the important answer to the above question after the data is gathered, crunched, analyzed and published.
Thanks for advancing science and public policy making in America regarding cannabis!
*The answer from the paper on medical cannabis’ impact on violent crime rates: ‘no’, violent crime rates do not rise because of the presence of medical cannabis retail stores.
Minnesota House and Senate lawmakers, along with Democrat Gov. Mark Dayton, agreed late last week to legislation that seeks to provide access to limited preparations of cannabis to qualified patients.
The finalized language represents a compromise between dueling House (House File 1818) and Senate bills (Senate File 1641), both of which had passed their respective chambers. On Friday afternoon, House lawmakers approved the compromised bill by a vote of 89 to 40. Members of the Senate voted 46 to 16 for the amended measure, sending it to the Governor’s desk.
Under the plan, state regulators intend to license two producers of cannabis and up to eight distribution centers. To be eligible to participate in the state’s program, patients need to possess a physician’s recommendation and be diagnosed with one of eight qualifying conditions (cancer/cachexia, glaucoma, HIV/AIDS, Tourette’s Syndrome, Amyotrophic Lateral Sclerosis, seizures — including those characteristic of epilepsy, severe and persistent muscle spasms — including those characteristic of multiple sclerosis, and/or Crohn’s Disease) and/or a terminal illness, and be registered with the state Department of Health.
Unlike other state medical cannabis programs, the Minnesota plan does not permit qualified patients to possess or obtain whole-plant cannabis. Instead, the forthcoming law mandates that state-licensed distribution centers provide oils, pills, and/or extracts prepared from the plant. Such products would be subject to laboratory testing for purity and potency. Patients’ health care provider must compile ongoing reports in regards to their patients’ progress.
Cannabis-based preparations are expected to be available to qualified patients by no later than July 1, 2015. Additional details on the forthcoming program are available here.